Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$11.8 million.

  • Corvus Pharmaceuticals' Net Cash Flow fell 1636.65% to -$11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year increase of 9604.11%. This contributed to the annual value of -$3.9 million for FY2024, which is 61985.16% down from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Net Cash Flow is -$11.8 million, which was down 1636.65% from $9.7 million recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Net Cash Flow ranged from a high of $12.4 million in Q3 2023 and a low of -$32.0 million during Q1 2022
  • Its 4-year average for Net Cash Flow is -$6.1 million, with a median of -$3.9 million in 2022.
  • In the last 5 years, Corvus Pharmaceuticals' Net Cash Flow surged by 42005.66% in 2023 and then tumbled by 105155.31% in 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' Net Cash Flow (Quarter) stood at -$11.4 million in 2022, then skyrocketed by 34.51% to -$7.5 million in 2023, then skyrocketed by 154.24% to $4.1 million in 2024, then tumbled by 391.23% to -$11.8 million in 2025.
  • Its last three reported values are -$11.8 million in Q3 2025, $9.7 million for Q2 2025, and -$3.7 million during Q1 2025.